Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Kokosis, G, Schmitz, R, Secord, AA, Havrilesky, LJ, Berchuck, A, Mantyh, CR, and Erdmann, D. "A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect." Gynakologe 47, no. 10 (January 1, 2014): 784-787.

Full Text

Havrilesky, LJ, and Fountain, C. "Can we maximize both value and quality in gynecologic cancer care? A work in progress." American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting (January 2014): e268-e275. (Review)

Full Text

Lewis, LS, Convery, PA, Bolac, CS, Valea, FA, Lowery, WJ, and Havrilesky, LJ. "Cost of care using prophylactic negative pressure wound vacuum on closed laparotomy incisions." Gynecologic Oncology 132, no. 3 (January 1, 2014): 684-689.

Full Text

Havrilesky, LJ. "Palliative services enhance the quality and value of gynecologic cancer care." Gynecologic oncology 132, no. 1 (January 2014): 1-2.

Full Text

Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (January 1, 2014): 3651-3659.

Full Text

Ricci, S, Giuntoli, RL, Eisenhauer, E, Lopez, MA, Krill, L, Tanner, EJ, Gehrig, PA, Havrilesky, LJ, Secord, AA, Levinson, K, Frasure, H, Celano, P, and Fader, AN. "Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?." Gynecologic Oncology 131, no. 3 (December 1, 2013): 629-633.

Full Text

Ricci, S, Giuntoli, RL, Eisenhauer, E, Lopez, MA, Krill, L, Tanner, EJ, Gehrig, PA, Havrilesky, LJ, Secord, AA, Levinson, K, Frasure, H, Celano, P, and Fader, AN. "Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?." Gynecologic Oncology 131, no. 3 (December 2013): 629-633.

Full Text

Moorman, PG, Havrilesky, LJ, Gierisch, JM, Coeytaux, RR, Lowery, WJ, Peragallo Urrutia, R, Dinan, M, McBroom, AJ, Hasselblad, V, Sanders, GD, and Myers, ER. "Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis." J Clin Oncol 31, no. 33 (November 20, 2013): 4188-4198. (Review)

Full Text

Havrilesky, LJ, Myers, ER, and Thomas, WL. "In reply." Obstet Gynecol 122, no. 5 (November 2013): 1114-. (Letter)

Full Text

Havrilesky, LJ, Myers, ER, and Thomas, WL. "Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer: A Systematic Review and Meta-analysis Reply." OBSTETRICS AND GYNECOLOGY 122, no. 5 (November 2013): 1114-1114.

Full Text

Pages